Related Experiment Video
Updated: Apr 30, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
9.1K
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion
David P Sonne1, Morten Hansen2, Filip K Knop2
1Diabetes Research DivisionDepartment of Medicine, Gentofte Hospital, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark dpsonne@gmail.com.
European Journal of Endocrinology
|April 25, 2014
Summary
Bile acid sequestrants, initially for high cholesterol, now improve type 2 diabetes control. They work by influencing bile acid signaling pathways, potentially involving glucagon-like peptide 1 (GLP1) secretion.
Area of Science:
- Endocrinology
- Metabolic Regulation
- Pharmacology
Background:
- Bile acid sequestrants traditionally treat hypercholesterolemia by interrupting bile acid recirculation.
- Emerging evidence highlights bile acids as metabolic regulators, acting as signaling molecules.
- Bile acids interact with nuclear receptors like FXR and G protein-coupled receptors like TGR5.
Purpose of the Study:
- To review the role of bile acid sequestrants in managing type 2 diabetes.
- To explore the mechanisms underlying their glucose-lowering effects.
- To investigate the potential involvement of incretin hormone secretion.
Main Methods:
- Literature review of studies on bile acid sequestrants and glycemic control.
- Analysis of the role of bile acids as signaling molecules.
- Discussion of receptor-mediated pathways, including TGR5 and GLP1.
Main Results:
- Bile acid sequestrants have demonstrated efficacy in improving glycemic control in type 2 diabetes.
- Bile acids act as hormones regulating lipid, glucose, and energy metabolism.
- Activation of TGR5 by bile acids may stimulate the secretion of glucagon-like peptide 1 (GLP1).
Conclusions:
- Bile acid sequestrants represent a therapeutic option for type 2 diabetes.
- Their mechanism involves bile acid signaling pathways, potentially via TGR5-mediated GLP1 secretion.
- Further research is needed to fully elucidate the complex mechanisms involved.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.3K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
953
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
953
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
993
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:24Type II Diabetes II: Pathophysiology
28
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28